BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Jan. 23, 2008
View Archived Issues
Novel lysosomal enzyme replacement therapy for MPS that crosses the BBB
Read More
Studies find little benefit of add-on lamotrigine in refractory schizophrenia patients
Read More
Argyll successfully completes first phase of formal proof of concept trial for SF-1019
Read More
Novel analgesic agents imparted in recent Vertex and Merck Frosst patents
Read More
New therapeutic agents for cardiovascular disorders reported in recent patents
Read More
Positive clinical trial results for epilepsy drug rufinamide in mood disorders
Read More
Recent patent discloses new therapeutic agents for liver diseases
Read More
Bionomics presents R&D update
Read More
Amarin provides pipeline update
Read More
Novel SMN2 promoter activator by deCODE may be useful in SMA
Read More
Genmab reaches two milestones in ofatumumab collaboration with GSK
Read More
Threshold provides update on several glufosfamide clinical trials
Read More
VIRxSYS signs research agreement with National Heart, Lung, and Blood Institute
Read More
Diamyd reports 30-month results from phase IIb study of diabetes vaccine Diamyd
Read More
LifeCycle reports interim results from phase II trial of LCP-Tacro in liver transplants
Read More
FDA approves Celsion's SPA application for phase III liver cancer trial of ThermoDox
Read More
StemCells reports death of patient in phase I clinical trial of HuCNS-SC for NCL
Read More
Tripep and Kringle Pharma apply for permission to initiate phase II study of ChronSeal
Read More
FDA has not yet made decision on Cardiome's and Astellas' NDA for Kynapid
Read More
Trophos completes enrollment of first 90 patients in phase IIa clinical trial of TRO-19622
Read More
Serenex and CHDI enter agreement to evaluate Hsp90 inhibitors for Huntington's disease
Read More
Synta initiates second phase I clinical trial of novel Hsp90 inhibitor STA-9090 in solid tumors
Read More
Positive phase III preliminary results reported for prolonged-release octreotide
Read More
Abraxis receives E.U. approval to market Abraxane for metastatic breast cancer
Read More
Additional indication for Astellas' Mycamine gets FDA approval
Read More
Fast track designation for Sabril in cocaine and methamphetamine dependence treatment
Read More
FDA accepts oral fludarabine NDA for review
Read More